Cyclacel Pharmaceuticals Inc. Stock
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.840% | 5.106% | 94.488% | 88.550% | 48.795% | -6.792% | -65.551% |
| Vaxart Inc. | 0.000% | 0.893% | 52.703% | 36.276% | 101.786% | -19.994% | -89.820% |
| Celldex Therapeutics | 0.760% | 3.937% | 39.683% | 41.176% | 20.000% | -35.389% | 16.300% |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat